Arcera Life Sciences, an international life sciences company headquartered in Abu Dhabi, UAE, and Innogen Pharmaceuticals (HKEX: 2591), a Shanghai-based biopharmaceutical company focused on metabolic diseases, have announced an exclusive licensing and commercialization agreement for Efsubaglutide Alfa, a GLP-1 receptor agonist therapy, across key international markets, including the UAE.
A Cross-Continental Licensing Agreement
The agreement, announced on November 19, 2026, spans selected countries in Africa, Eastern Europe, Latin America, and the Middle East.
Under its terms, Arcera will be responsible for regulatory activities, market access, and commercialization of the therapy across the agreed territories. Innogen will receive an upfront payment and will be eligible for milestone payments and tiered royalties on net sales of the product in the licensed territories.
The deal marks a significant step in Arcera's strategy to strengthen its cardiometabolic franchise and broaden its portfolio of innovative medicines across international markets, establishing cardiometabolic disease as a core pillar of the company's portfolio.
It also reflects Arcera's stated ambition to be a partner of choice for bringing differentiated innovative medicines to patients in international markets.
Executive Perspectives
Isabel Afonso, Chief Executive Officer of Arcera Life Sciences, said, "Cardiometabolic diseases remain among the most pressing healthcare challenges in the markets we serve. Our agreement with Innogen accelerates the bridge we are building between China and our international markets to bring innovative medicines to more patients and strengthen our cardiometabolic portfolio. By combining our partners' scientific capabilities with Arcera's regulatory expertise, market access, and overall commercial reach, we aim to turn innovation into meaningful impact for people living with chronic disease."
Dr. Qinghua Wang, Founder, Chairman and Chief Executive Officer of Innogen Pharmaceuticals, said, "We are delighted to establish this collaboration with Arcera, which represents an important step in Innogen's international expansion. We believe that combining world-class science with entrepreneurial innovation is key to improving patient care. Innogen's mission is to provide best-in-class and first-in-class therapies for people living with diabetes, obesity, and other metabolic diseases worldwide."
Trusted by Leading EPCs & Manufacturers
Find the Latest Pharmaceutical Plant Projects Around the World
Gain exclusive access to our industry-leading database of pharmaceutical plant opportunities with detailed project timelines and stakeholder information
Request Free Trial → Learn More →
No credit card Up-to-date coverage
The Disease Landscape Driving the Deal
Cardiometabolic diseases, including obesity and type 2 diabetes, represent a substantial and growing healthcare burden globally. According to the International Diabetes Federation, 589 million adults worldwide are living with diabetes, a number projected to reach 853 million by 2050.
The partnership between Arcera and Innogen is positioned as a step toward wider access to advanced metabolic therapies. GLP-1 receptor agonists are a class of therapy used in the management of type 2 diabetes and, increasingly, obesity.
In 2025, the World Health Organization added GLP-1 therapies to its Model List of Essential Medicines and issued a global guideline on their use in treating obesity, a condition affecting more than one billion people worldwide.
For Arcera, the agreement strengthens its presence in this therapy area and creates a platform for further growth in cardiometabolic medicine across its international markets.
Clinical Profile of Efsubaglutide Alfa
Efsubaglutide Alfa is a fusion protein comprising a human GLP-1 analogue and an IgG Fc fragment, with a half-life of up to 280 hours across different studies. Clinical studies showed HbA1c reductions of approximately 2.2 percentage points at Week 24.
In clinical studies in Chinese adults with overweight or obesity, 18 weeks of treatment achieved average weight reductions of 10.6% with once-weekly (QW) dosing and 9.7% with once-every-two-weeks (Q2W) dosing.
The study also observed improvements in body composition. The muscle-to-fat ratio increased by up to 45.3% from baseline with QW dosing, with weight loss driven predominantly by a reduction in fat mass, indicating fat reduction and relative preservation of muscle. Liver fat content was reduced by up to 51.8% with QW dosing.
Safety and Tolerability Findings
According to the announcement, the incidence of gastrointestinal adverse events was low relative to other GLP-1 receptor agonists, based on cross-trial comparisons. No participants discontinued treatment due to adverse events during an 18-week treatment period, and the treatment was well tolerated.
Innogen has also completed a Phase II clinical trial in adults with overweight or obesity in Australia, evaluating the efficacy and safety of once-monthly (Q4W) dosing. The study generated further clinical evidence to support the product's future global registration and commercialization.
Strategic Context
The agreement brings together Innogen's expertise in metabolic diseases with Arcera's regulatory, market access, and commercial capabilities.
Both companies frame the deal as combining scientific innovation with commercial reach to expand patient access to metabolic therapies, with Arcera describing the collaboration as accelerating the bridge between China and its international markets, and Innogen characterizing it as an important step in its international expansion.
Your Gateway to Every Project in the Global Chemical Sector
Staying ahead in the global chemical sector's dynamic landscape means being aware of upcoming developments before your competitors do. New projects are initiated, tenders are issued, and contracts are finalized every single day; spanning manufacturing, research, infrastructure, and beyond.
The Global Project Tracking (GPT) platform by Blackridge Research consolidates vital information specific to the chemical sector, encompassing projects at every phase of development and across all regions. Say goodbye to fragmented data, overlooked prospects, and delayed market entry.
Whether you're pursuing new opportunities, monitoring industry trends, or strategizing growth, timely project data in the chemical sector is the key to staying ahead and driving innovation.
Upcoming Projects
Tender Notices
Contract Awards
Projects Under Construction
Completed Projects
Book a Free Demo today and discover how the Global Project Tracking (GPT) platform by Blackridge Research can assist you in seizing opportunities within the worldwide chemical sector first.
Leave a Comment
We love hearing from our readers and value your feedback. If you have any questions or comments about our content, feel free to leave a comment below.
We read every comment and do our best to respond to them all.